Alzheimer’s disease is the most common cause of dementia and one of the biggest health challenges facing the world today. It gradually damages memory, thinking abilities, and the capacity to perform everyday tasks.
In the early stages, people may forget recent conversations or misplace objects more often. As the disease progresses, many struggle to recognize loved ones, communicate clearly, or live independently.
Scientists have spent decades trying to understand exactly what causes Alzheimer’s disease. One of the main suspects is a sticky protein called amyloid-beta. In healthy brains, small amounts of this protein are produced and then removed.
However, in Alzheimer’s disease, amyloid-beta begins to accumulate and form clumps called plaques. These plaques are believed to damage brain cells and interfere with communication between neurons.
The brain normally has ways to remove unwanted materials. One important structure involved in this process is the blood-brain barrier. This barrier acts like a highly selective filter between the brain and the bloodstream.
It allows essential nutrients to enter the brain while keeping potentially harmful substances out. It also plays an important role in helping remove waste products from the brain.
A special group of proteins called P-glycoprotein pumps, often shortened to P-gp, helps carry amyloid-beta out of the brain and into the bloodstream. Scientists have found that these pumps become much weaker in people with Alzheimer’s disease. When these pumps fail, toxic proteins can build up and become trapped in the brain.
Researchers at Monash University in Australia have now reported promising results from laboratory experiments involving an experimental drug called Cu(ATSM). Their findings were published in the journal ACS Chemical Neuroscience.
Cu(ATSM) is a copper-containing compound that can deliver copper to the brain. Copper is a mineral that the body needs in small amounts for many biological processes, including energy production and normal brain function. Researchers believe that disturbances in metal balance may contribute to several neurological diseases.
The Monash team wanted to see whether Cu(ATSM) could repair the brain’s waste-removal system and reduce the buildup of harmful proteins.
The researchers used laboratory models of Alzheimer’s disease and found that treatment with Cu(ATSM) increased the number of P-glycoprotein pumps by about 24 percent. By strengthening these pumps, the brain became better able to remove amyloid-beta.
After 56 days of treatment, levels of toxic amyloid-beta were reduced by 42 percent. The researchers also found that memory performance improved significantly. Spatial learning, which involves remembering locations and navigating environments, improved by nearly 44 percent.
Lead author Dr. Jae Pyun said the study is the first to demonstrate a direct link between repairing the blood-brain barrier’s waste-clearing pumps, lowering toxic protein levels, and improving cognitive function.
The researchers believe the treatment may work in more than one way. Besides restoring the waste-clearing pumps, Cu(ATSM) may also help activate microglia, which are immune cells that naturally live in the brain. Microglia help remove debris and may also break down amyloid plaques.
One reason scientists are excited about Cu(ATSM) is that it has already undergone safety testing for other neurological conditions, including Parkinson’s disease and amyotrophic lateral sclerosis, also known as ALS. This could potentially speed up future clinical studies in Alzheimer’s disease.
Professor Joseph Nicolazzo, senior author of the study and director of the Center for Drug Candidate Optimization at Monash Institute of Pharmaceutical Sciences, said the findings provide strong support for testing the drug in people with early symptomatic Alzheimer’s disease.
The study has several strengths. It did not simply measure changes in protein levels. It also showed improvements in memory-related behavior, which is important because preserving cognitive function is the ultimate goal of Alzheimer’s treatment. The study also identified a new target for therapy by focusing on the brain’s waste-clearance system and blood vessels.
However, the findings should be interpreted cautiously. The research was conducted in laboratory models and not in human patients. Scientists still do not fully understand exactly how the proteins leave the brain after treatment.
Larger studies and human clinical trials will be necessary before researchers know whether the drug can safely and effectively help people with Alzheimer’s disease.
Even so, the study offers hope. Alzheimer’s disease and other forms of dementia are becoming increasingly common as populations age. In Australia, dementia has recently become the leading cause of death.
Finding treatments that slow or prevent cognitive decline has become a global priority. By helping the brain clear away toxic waste, Cu(ATSM) may represent a promising new direction in the fight against Alzheimer’s disease.
If you care about Alzheimer’s disease, please read studies that bad lifestyle habits can cause Alzheimer’s disease, and strawberries can be good defence against Alzheimer’s.
For more information about brain health, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
Source: Monash University.
